San Diego, CA -- (SBWIRE) -- 05/03/2017 -- The Shareholders Foundation announces that a deadline is coming up on June 5, 2017 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Revance Therapeutics Inc (NASDAQ:RVNC) between June 19, 2014 and May 1, 2015, and pursuant and/or traceable to the Registration Statement and prospectus for the company's June 19, 2014 Public Offering.

Investors who purchased a significant amount of shares of Revance Therapeutics Inc (NASDAQ:RVNC) between June 19, 2014 and May 1, 2015, and pursuant and/or traceable to the Registration Statement and prospectus for the company's June 19, 2014 Public Offering, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call 858-779-1554.

The settlement proof of claim form or detailed settlement notice for the settlement in the Revance Therapeutics Inc (NASDAQ:RVNC) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/revance-therapeutics-inc-nasdaq-rvnc-investor-securities-class-action-lawsuit-06102015

In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is June 5, 2017. The class action administrator for this case is Gilardi & Co LLC.

The lawsuit was filed over alleged violations of Federal Securities Laws by Revance Therapeutics Inc regarding certain allegedly false and misleading statements made in connection with Revance Therapeutics Inc's June 19, 2014 follow-on public stock offering. According to the complaint the plaintiff alleges on behalf of purchasers of Revance Therapeutics Inc (NASDAQ:RVNC) common stock in its June 19, 2014 follow-on public stock offering, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Registration Statement issued in connection with the June 19, 2014 follow-on public stock offering allegedly failed to disclose, among other things, that Revance Therapeutics Inc had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014, and that Revance Therapeutics Inc did not have the quality or quantity of RT001 on hand sufficient to complete and successful Phase 3 clinical trial.

Those who purchased shares of Revance Therapeutics Inc (NASDAQ:RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com